MG53: A new protagonist in the precise treatment of cardiomyopathies

Biochem Pharmacol. 2024 Apr:222:116057. doi: 10.1016/j.bcp.2024.116057. Epub 2024 Feb 15.

Abstract

Cardiomyopathies (CMs) are highly heterogeneous progressive heart diseases characterised by structural and functional abnormalities of the heart, whose intricate pathogenesis has resulted in a lack of effective treatment options. Mitsugumin 53 (MG53), also known as Tripartite motif protein 72 (TRIM72), is a tripartite motif family protein from the immuno-proteomic library expressed primarily in the heart and skeletal muscle. Recent studies have identified MG53 as a potential cardioprotective protein that may play a crucial role in CMs. Therefore, the objective of this review is to comprehensively examine the underlying mechanisms mediated by MG53 responsible for myocardial protection, elucidate the potential role of MG53 in various CMs as well as its dominant status in the diagnosis and prognosis of human myocardial injury, and evaluate the potential therapeutic value of recombinant human MG53 (rhMG53) in CMs. It is expected to yield novel perspectives regarding the clinical diagnosis and therapeutic treatment of CMs.

Keywords: Biomarker; Cardiokine; Cardiomyopathy; MG53; TRIM protein; rhMG53.

Publication types

  • Review

MeSH terms

  • Cardiomyopathies* / drug therapy
  • Cardiomyopathies* / metabolism
  • Heart
  • Humans
  • Muscle, Skeletal / metabolism
  • Myocardium* / metabolism
  • Treatment Outcome